Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive

Bayer Links

• Bayer Global
• Sustainability
• Press
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Investor News

Search

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Wednesday May 16, 2012

Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO):

Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012

First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session

Wednesday May 09, 2012

Not intended for U.S. and UK media

Bayer's Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

Wednesday May 02, 2012

Not intended for U.S. and UK media:

Bayer's Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE

Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Friday April 27, 2012

Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG:

Bayer has great potential for the future too

Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1

Thursday April 26, 2012

1st quarter of 2012:

Encouraging start to the year for Bayer

Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience - increases at HealthCare - continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed

Wednesday April 25, 2012

Not intended for US or UK use - Aesthetic medicine:

Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat

Friday April 20, 2012

New fungicidal seed treatment product for oilseed rape:

First approval worldwide for EverGol^TM in seed treatment

Launch in Canada planned before the end of the year

Sunday April 15, 2012

Not intended for U.S. and UK media - Molecular Imaging:

Bayer sells PET tracers to Piramal

Thursday April 12, 2012

Not intended for U.S. and UK media

Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE

Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE

Wednesday April 11, 2012

Not intended for U.S. and UK media

Bayer Updates U.S. Labels for Drospirenone-containing Combined Oral Contraceptives

Tuesday April 03, 2012

Not intended for U.S. and U.K. Media

Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival

Monday March 26, 2012

Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):

Bayer's Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study

Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine

Monday March 19, 2012

Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):

Results of the Phase III EINSTEIN-PE Study with Bayer's Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012

Thursday March 15, 2012

Not intended for U.S. and UK Media

U.S. FDA approves Natazia^TM as the first combined oral contraceptive to treat heavy menstrual bleeding (HMB)

Wednesday March 14, 2012

"Meet Management" investor conference:

Bayer sets ambitious targets for 2014

Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position

Tuesday February 28, 2012

Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):

Bayer's Xarelto® (Rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS

Tuesday February 28, 2012

Financial and innovation targets for 2011 achieved

Bayer: sales and EBIT at record levels

Sales increase by 4.1 percent to EUR 36,528 million / Operating result (EBIT) improves by 52.0 percent to EUR 4,149 million / EBITDA before special items advances by 7.2 percent to EUR 7,613 million / Growth at HealthCare and CropScience, decline in momentum at MaterialScience / Net income climbs by 89.9 percent to EUR 2,470 million / Success of new products creates optimism for the future / Presence in emerging markets further expanded / Forecast for 2012: slight increase in underlying earnings

Thursday February 23, 2012

Elections to the Supervisory Board to be held at the Annual Stockholders' Meeting on April 27, 2012

Werner Wenning to be proposed as Chairman of the Supervisory Board of Bayer AG

Dr. Manfred Schneider to remain in office until September 30, 2012 / Two candidates nominated for election as new stockholder representatives / Stockholders to resolve on a new compensation system for the members of the Supervisory Board

Thursday February 23, 2012

Bayer plans dividend increase for 2011 to EUR 1.65 per share

Payout to rise by 10 percent to EUR 1,364 million

Monday February 20, 2012

Not intended for U.S. and UK Media

Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye

Tuesday February 14, 2012

Bayer CropScience receives approval from the EPA:

New fungicide Luna_TM registered in the USA

Friday January 27, 2012

Milestone for stacked insect-resistant, herbicide-tolerant cotton

Bayer CropScience's TwinLink® cotton technology receives full authorization in the US

Wednesday January 18, 2012

Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:

Bayer's Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Wednesday January 18, 2012

Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:

Positive Phase III Data on Bayer's Investigational Drug Regorafenib Show Significant Increase in Overall Survival

First presentation of data from CORRECT trial as "Late Breaking Abstract" at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)

Tuesday January 10, 2012

Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):

Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012

Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012